Exit Orchid Chemicals, says Thununguntla

HYDERABAD: Israeli drugmaker Teva Pharmaceutical Industries has settled patent dispute with the Indian pharmaceutical firm Orchid Chemicals & Pharmaceuticals pertaining to Parkinson's disease drug Azilect (rasagiline mesylate) in the US market. Both ...

Orchid Chemicals & Pharmaceuticals has received an approval to extend date till June 30, 2013 for Business Transfer Agreement (BTA) with Hospira. The board of directors at its meeting held on April 17, 2013, has approved the same. Orchid Chemicals & ...

Orchid Chemicals and Pharmaceuticals are trading higher by almost 4% to Rs 69.10, extending its previous day’s 5% rally after the company said Cephalosporin API manufacturing complex located in Alathur has cleared the US Food and Drug Administration ...

Orchid Chemicals Pharmaceuticals Ltd has informed BSE that Orchid's Cephalosporin API manufacturing complex located in Alathur, Chennai has successfully cleared the USFDA inspection that it went through.

Sudarshan Sukhani Technical Analyst Sukhani told CNBC-TV18, "Orchid Chemicals and Pharmaceuticals is a short sell. It is an avoid. By no stretch of imagination is it a buy. One should just stay away." At 10:04 hrs Orchid Chemicals and ...

28-Apr-2013 | Source : AG-IP News | Visits : 198 NEW DELHI - Thermax Engg, Triveni Turbine, Orchid Chemical and MSN Lab among winners of IP Awards for 2013, Pune-based engineering major Thermax Limited has won the National Intellectual Property ...

Terming the death of Dr.Reddy's Laboratories founder Kallam Anji Reddy a "personal loss", Orchid Chemicals and Pharmaceuticals Ltd chief K. Raghavendra Rao said he was a combination of a good leader, pioneer, businessmen, friend, mentor, and human being in ...

Financing for development of novel antibiotic treatments in partnership with Orchid Chemicals & Pharmaceuticals Ltd. Munich, Germany and Naarden, The Netherlands, 18 April 2013 Forbion Capital Partners, the Dutch life sciences venture capital firm, ...

Orchid Chemicals & Pharmaceuticals , an Indian pharmaceutical company based in Chennai, plunged on Thursday after it posted a net loss of Rs 1,322.68 million for the quarter ended Mar. 31, 2013 compared to net profit of Rs 205.51 million last year. Total ...